Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of March 20th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for CNOOC, Alibaba, CCB, Tencent, Lingbao Gold, SMIC, CHALCO, Sinopec, HSBC, Cmoc.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of March 20th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for CNOOC, Alibaba, CCB, Tencent, Lingbao Gold, SMIC, CHALCO, Sinopec, HSBC, Cmoc.


HK Connect Flows Weekly (Mar 20th): CNOOC, Alibaba, CCB, Tencent, Lingbao Gold, SMIC, CHALCO

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Genfleet Therapeutics / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/genfleet-therapeutics" target="_blank" data-smartkarma-citation="entities:44187:1" rel="noopener">GenFleet Therapeutics</a> (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its cornerstone investors is set to expire soon.</li>
<li>GFT is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology.</li>
<li>In this note, we will talk about the lockup dynamics and possible placement.</li>
</ul>



GenFleet Therapeutics (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its cornerstone investors is set to expire soon.
GFT is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology.
In this note, we will talk about the lockup dynamics and possible placement.


GenFleet Therapeutics IPO Lockup - A Minor Prelude to a Much Bigger Release

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of February 27th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Tencent, Alibaba, Xiaomi, Meituan, Hua Hong Semiconductor, Zijin Mining.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of February 27th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Tencent, Alibaba, Xiaomi, Meituan, Hua Hong Semiconductor, Zijin Mining.


HK Connect Flows Weekly (Feb 27th): Tencent, Alibaba, Xiaomi, Meituan, Hua Hong Semiconductor

<ul>
<li>We analysed the earning revision of component stocks of HS TECH in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on MEITUAN, JD.COM, TENCENT, XPENG, BYD, Kuaishou, NIO.</li>
</ul>


We analysed the earning revision of component stocks of HS TECH in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on MEITUAN, JD.COM, TENCENT, XPENG, BYD, Kuaishou, NIO.


HS TECH Index Earning Revision (Feb): MEITUAN, JD.COM, TENCENT, XPENG, BYD, Kuaishou, NIO

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Good Doctor Cloud Healthcare & Technology Group / Equity Capital Markets

Good Doctor Cloud Healthcare & Technology Group (GDC HK)

Good Doctor Cloud Healthcare & Technology Group

<ul>
<li>The business model of GOOD DOCTOR CLOUD (CDC) is more of a “middleman”, so its profits is largely dependent on the “price difference” and continuous expansion of customer base.</li>
<li>Short-Term strong demand brought by COVID-19 won’t last. If customer growth fails to meet expectations, long-term performance growth will gradually decline, and even lead to the recurrence of losses.</li>
<li>Although CDC has turned losses into profits, the current earnings are still unstable. Therefore, we suggest using the P/S ratio for valuation, which should be lower than peers.</li>
</ul>


The business model of GOOD DOCTOR CLOUD (CDC) is more of a “middleman”, so its profits is largely dependent on the “price difference” and continuous expansion of customer base.
Short-Term strong demand brought by COVID-19 won’t last. If customer growth fails to meet expectations, long-term performance growth will gradually decline, and even lead to the recurrence of losses.
Although CDC has turned losses into profits, the current earnings are still unstable. Therefore, we suggest using the P/S ratio for valuation, which should be lower than peers.


Pre-IPO Good Doctor Cloud Healthcare & Technology Group - Pain Points of Business Models and Outlook

China

JD Health International Inc. is a Chinese online healthcare platform and retail pharmacy. It provides pharmaceutical and healthcare products, internet healthcare services, health management, and intelligent healthcare solutions. The company was founded in February 2014 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JD Health (6618 HK)

HK Connect Flows Weekly (Mar 20th): CNOOC, Alibaba, CCB, Tencent, Lingbao Gold, SMIC, CHALCO

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for CNOOC, Alibaba, CCB, Tencent, Lingbao Gold, SMIC, CHALCO,...

Ke Yan, CFA, FRM

GenFleet Therapeutics IPO Lockup - A Minor Prelude to a Much Bigger Release

GenFleet Therapeutics (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its cornerstone investors is set to expire...

Sumeet Singh

HK Connect Flows Weekly (Feb 27th): Tencent, Alibaba, Xiaomi, Meituan, Hua Hong Semiconductor

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent, Alibaba, Xiaomi, Meituan, Hua Hong...

Ke Yan, CFA, FRM

HS TECH Index Earning Revision (Feb): MEITUAN, JD.COM, TENCENT, XPENG, BYD, Kuaishou, NIO

We analyzed HS TECH's consensus for Feb 2026 and highlighted changes of EPS in MEITUAN, JD.COM, TENCENT, XPENG, BYD, Kuaishou, NIO.

Ke Yan, CFA, FRM

Pre-IPO Good Doctor Cloud Healthcare & Technology Group - Pain Points of Business Models and Outlook

GOOD DOCTOR CLOUD's profits rely on price difference/customer base growth.Short-term high growth won't last.Long-term success hinges on meeting...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

HK Connect Flows Weekly (Mar 20th): CNOOC, Alibaba, CCB, Tencent, Lingbao Gold, SMIC, CHALCO

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for CNOOC, Alibaba, CCB, Tencent, Lingbao Gold, SMIC, CHALCO,...

Ke Yan, CFA, FRM

GenFleet Therapeutics IPO Lockup - A Minor Prelude to a Much Bigger Release

GenFleet Therapeutics (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its cornerstone investors is set to expire...

Sumeet Singh

HK Connect Flows Weekly (Feb 27th): Tencent, Alibaba, Xiaomi, Meituan, Hua Hong Semiconductor

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent, Alibaba, Xiaomi, Meituan, Hua Hong...

Ke Yan, CFA, FRM

HS TECH Index Earning Revision (Feb): MEITUAN, JD.COM, TENCENT, XPENG, BYD, Kuaishou, NIO

We analyzed HS TECH's consensus for Feb 2026 and highlighted changes of EPS in MEITUAN, JD.COM, TENCENT, XPENG, BYD, Kuaishou, NIO.

Ke Yan, CFA, FRM

Pre-IPO Good Doctor Cloud Healthcare & Technology Group - Pain Points of Business Models and Outlook

​GOOD DOCTOR CLOUD's profits rely on price difference/customer base growth.Short-term high growth won't last.Long-term success hinges on meeting...

Xinyao (Criss) Wang

GOOD DOCTOR CLOUD's profits rely on price difference/customer base growth.Short-term high growth won't last.Long-term success hinges on meeting...